Goldman Sachs’ Dana Flanders sheds new insights on Valeant from a bearish standpoint, spotting 5% in loss potential for the stock.
Summit Redstone’s Jonathan Kees thinks the market is underestimating Twitter’s turnaround.
Cowen’s Georgios Mihalos makes a neutral case on Square’s opportunity, giving kudos to its “Build with Square” integrated strategy, but seeing growth opportunities priced into the current stock price.
Guggenheim’s Rohit Vanjani puts a price tag on Revance Therapeutics.
Canaccord’s John Newman sees 24% upside potential for BLUE shares.
Oppenheimer’s Hartaj Singh sees 227% upside potential for CLSN.
Wells Fargo’s Aaron Rakers sees 14% upside potential for AAPL stock, but spotlights volatility down the line.
Maxim is confident that HMNY’s recent 52% purchase of MoviePass will usher in commercial leverage.
Analyst initiates a bullish perspective on Dynavax, ascribing a probability of 95% approval for its lead asset.
Analyst Swayampakula Ramakanth of H.C.